{
    "clinical_study": {
        "@rank": "4674", 
        "arm_group": [
            {
                "arm_group_label": "700 \u03bcg Dexamethasone", 
                "arm_group_type": "Experimental", 
                "description": "700 \u03bcg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) intravitreal injection in the study eye on Day 1 and Month 6."
            }, 
            {
                "arm_group_label": "Sham and 700 \u03bcg Dexamethasone", 
                "arm_group_type": "Other", 
                "description": "Sham Posterior Segment Drug Delivery System administered in the study eye on Day 1 and 700 \u03bcg Dexamethasone Posterior Segment Drug Delivery System intravitreal injection at Month 6."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of 700 \u03bcg dexamethasone Posterior Segment\n      Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a  6\n      month double-blind period versus sham followed by a  2 month open label period."
        }, 
        "brief_title": "Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema", 
                "Retinal Vein Occlusion"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Presence of macular edema defined as macular thickening involving the center of the\n        macula due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion\n        (CRVO)\n\n        Exclusion Criteria:\n\n          -  History of glaucoma, ocular hypertension or optic nerve head change\n\n          -  Any active bacterial, viral, parasitic, or fungal infections in either eye\n\n          -  Eye surgery, including cataract surgery, and/or laser of any type in the study eye\n             within 3 months prior to study start\n\n          -  History of use of intravitreal steroids or any intravitreal injectable drug in the\n             study eye within 3 months prior to study start\n\n          -  Use of oral, intravenous, intramuscular, epidural, rectal, or extensive dermal\n             steroids within 1 month prior to study start\n\n          -  Use of immunosuppressants, immunomodulators, antimetabolites, and/or alkylating\n             agents within 3 months prior to study start\n\n          -  Use of topical ophthalmic corticosticosteroids within 2 weeks of study start"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "265", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660802", 
            "org_study_id": "206207-020"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "700 \u03bcg Dexamethasone", 
                    "Sham and 700 \u03bcg Dexamethasone"
                ], 
                "description": "700 \u03bcg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) intravitreal injection in the study eye at Day 1 and Month 6 or Month 6 only.", 
                "intervention_name": "700 \u03bcg Dexamethasone", 
                "intervention_type": "Drug", 
                "other_name": "Ozurdex\u00ae"
            }, 
            {
                "arm_group_label": "Sham and 700 \u03bcg Dexamethasone", 
                "description": "Sham Posterior Segment Drug Delivery System administered in the study eye on Day 1.", 
                "intervention_name": "Sham", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Best Corrected Visual Acuity (BCVA)", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660802"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Central Retinal Thickness as assessed by Optical Computer Tomography (OCT)", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Fluorescein leakage as assessed by fluorescein angiography (FA)", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}